- About |
- Contact Us |
- Site Map |
- Privacy Policy |
- Terms Of Use |
- Feedback
5. Science and Technology for Disease Control: Past, Present, and Future
CUSTOM BOOKS
Select, organize, download, and save your choice of chapters into a single PDF file for printing and distribution. This is a free service.
My DCPP
Log in to view your saved custom books
CHAPTER INFO
Editors/Authors: David Weatherall, Brian Greenwood, Heng Leng Chee, and Prawase Wasi
Pages: 20
Region
East Asia and Pacific
High Income OECD
Latin America and the Caribbean
Middle East and North Africa
Other High Income
South Asia
Disease / Condition
Addictions
Adolescent & Childhood Diseases
Blood-Related Diseases
Cancers
Cardiovascular Disease
Diabetes
HIV/AIDS
Infectious Diseases
Learning & Developmental Disabilities
Malaria
Maternal & Neonatal Conditions
Mental Disorders
Neurological Disorders
Noncommunicable Diseases
Nutrition
Tropical Diseases
Tuberculosis
Vaccine-Preventable Diseases
Abstract
Despite increasingly rapid advances in the biomedical sciences, people in many developing countries are still living in dire poverty with limited access to basic health care. This situation demands international attention, especially given the potential for science and technology to control disease and improve lives. Modern medicine has seen the steady accumulation of knowledge and know–how, culminating in the partial control of infectious diseases and the management of noncommunicable diseases. Many countries in the developing world, however, are caught in an epidemiological transition: they must simultaneously tackle malnutrition and infectious diseases as well as diseases commonly associated with industrial countries, such as cardiovascular disease, obesity, and diabetes.
Advances in the biomedical sciences have made only a limited contribution to the health of developing countries, in part because the industrial world has neglected the specific health problems or health care delivery challenges of these countries. To achieve health gains in the developing world, a balance needs to be struck between reliance on new biomedical strategies and the continued application of more conventional methods in the most cost–effective manner. This entails closer interaction between the fields of basic and clinical research and the fields of public health and health economics.
Moreover, medical research will need to take on a global perspective. Both governmental agencies and charitable bodies in industrial countries will need to direct a greater proportion of their funding to diseases of the developing world. In addition, universities in industrial countries will need to provide future medical scientists with a more global understanding of health and disease. In this way, the promise and benefits of biomedical research and good practice can be more evenly distributed among the populations of the world.
Sections
Click on the links below to read the full text.
Figures
- 5.1 Effects of a One-Hour Streptokinase Infusion Together with Aspirin for One Month on the 35-Day Mortality in the Second International Study of Infarct Survival Trial among 17,187 Patients with Acute Myocardial Infarction Who Would Not Normally Have Received Streptokinase or Aspirin, Divided at Random into Four Groups to Receive Aspirin Only, Streptokinase Only, Both, or Neither
- 5.2 Decline in Serious Forms of Thalassemia in Different Populations after the Initiation of Prenatal Diagnosis in 1972 following the Development of North-South Partnerships.
